Prognostic and Therapeutic Applications of RKIP in Cancer
- 1st Edition - February 3, 2020
- Imprint: Academic Press
- Editors: Benjamin Bonavida, Stavroula Baritaki
- Language: English
- Hardback ISBN:9 7 8 - 0 - 1 2 - 8 1 9 6 1 2 - 0
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 2 2 4 5 1 - 9
Prognostic and Therapeutic Applications of RKIP in Cancer provides updated reviews on the chemistry, signaling, pre-clinical and clinical activities, and role of RKIP expressio… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quotePrognostic and Therapeutic Applications of RKIP in Cancer provides updated reviews on the chemistry, signaling, pre-clinical and clinical activities, and role of RKIP expression levels for diagnostics, prognosis and potential interventions. The development of novel compounds and conjugates that selectively induce RKIP expression in cancer open a novel era of new therapeutics and their potential in the treatment of highly resistant cancers and metastases. Edited and written by internationally renowned experts in the field of novel therapeutics for cancer, this book is a valuable source for cancer researchers, medical scientists, clinicians, clinical pharmacologists, and graduate students.
- Provides an update from experts in the field on diagnostics, prognostics and therapeutics
- Brings a clear overview of recent findings and references, as well as summaries, significant molecular pathways, and conclusions in each chapter
- Provides a general introductory chapter on contributions in the field and a chapter summary, with synthesized findings and a projection of future goals
Cancer researchers, medical scientists, clinicians, graduate students
- Edition: 1
- Published: February 3, 2020
- No. of pages (Hardback): 504
- No. of pages (eBook): 504
- Imprint: Academic Press
- Language: English
- Hardback ISBN: 9780128196120
- eBook ISBN: 9780128224519
BB
Benjamin Bonavida
Dr Bonavida has vast expertise and various reported publications in the field of tumor cell sensitization to chemotherapy (a total of greater than 500 publications) and in particular the novel role of Nitric Oxide (NO) donors in chemo-sensitization and reversal of drug resistance. In addition, he was the first scientist to co-organize an international meeting on the topic (First International Workshop on NO and Cancer, 2005).
Affiliations and expertise
Professor, Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, University of California, USASB
Stavroula Baritaki
Stavroula Baritaki’s, PhD, is currently Professor in Experimental Oncology at the University of Greece,. Her areas of expertise include the understanding of the molecular mechanisms involved in tumour cell therapeutic resistance and acquisition of a metastatic phenotype. Her studies have revealed novel gene products, including Raf-1 Kinase inhibitory protein (RKIP),. Followed by further studies on the epigenetic and post-translational regulation of RKIP in many cancer types, her overall findings have firstly suggested the RKIP downregulation in cancer cells as a putative gene signature of tumor chemo/immune-resistance and EMT with prognostic and therapeutic significance in an individualized basis. On this context, Dr. Baritaki has extended her research interests in identifying novel agents that through RKIP induction are able to inhibit EMT or improve either the host immunosurveillance and/or the efficacy of anti-tumor therapies, especially if they are combined with conventional immuno-stimulatory or chemotherapeutic regimens. Most of these agents are currently under clinical trials.
Affiliations and expertise
Division of Surgical Oncology, School of Medicine, University of Crete, Heraklion, Crete, GreeceRead Prognostic and Therapeutic Applications of RKIP in Cancer on ScienceDirect